| Protocol | In Vitro | In vitro activity: Tizoxanide is the active metabolite of Nitazoxanide, which is a thiazolide anti-infective compound against anaerobic bacteria, protozoa, and a range of viruses. IC50 value: Target: Antiviral agent in vitro: Tizoxanide inhibited virus replication of all CIVs with 50% and 90% inhibitory concentrations ranging from 0.17 to 0.21 μM and from 0.60 to 0.76 μM, respectively. Nitazoxanide and its primary metabolite, tizoxanide, inhibit hepatitis C virus (HCV) replication in HCV replicon systems. Interestingly, serial passage in nitazoxanide or tizoxanide resulted in increased sensitivity to alpha interferon 2b: EC(50)s and EC(90)s were reduced three- and eightfold, respectively. Kinase Assay: Cell Assay: |
|---|
| In Vivo | Nitazoxanide is partially effective at reducing the parasite burden in a gnotobiotic piglet diarrhea model when given orally for 11 days at 250 mg/kg/day but not at 125 mg/kg/day. Nitazoxanide induces a drug-related diarrhea in piglets that might have influenced its therapeutic efficacy. |
|---|
| Animal model | Sprague Dawley rats |
|---|
| Dosages | 10 mg/kg |
|---|
| Administration | Tizoxanide (10 mg/kg; i.v.) |
|---|
These protocols are for reference only. InvivoChem does not
independently validate these methods.
Preparing Stock Solutions
| Solvent volume to be added |
Mass (the weight of a compound) |
| Mother liquor concentration |
1mg | 5mg | 10mg | 20mg |
| 1mM | 3.7700 mL | 18.8501 mL | 37.7003 mL | 75.4006 mL |
|---|
| 5mM | 0.7540 mL | 3.7700 mL | 7.5401 mL | 15.0801 mL |
|---|
| 10mM | 0.3770 mL | 1.8850 mL | 3.7700 mL | 7.5401 mL |
|---|
| 20mM | 0.1885 mL | 0.9425 mL | 1.8850 mL | 3.7700 mL |
|---|
|
Quality Control Documentation
|
|
: 
